Katharina Kerschan-Schindl1, Wolfgang Gruther2,3, Ursula Föger-Samwald4, Christine Bangert5, Stefan Kudlacek6, Peter Pietschmann4. 1. Department of Physical Medicine and Rehabilitation and Occupational, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. katharina.kerschan-schindl@meduniwien.ac.at. 2. Department of Physical Medicine and Rehabilitation and Occupational, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. 3. healthPi - Medical Center, Vienna, Austria. 4. Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria. 5. Department of Dermatology, Medical University of Vienna, Vienna, Austria. 6. Medizinische Abteilung, Krankenhaus Barmherzige Brüder, Vienna, Austria.
Abstract
BACKGROUND: In dermatomyostis (DM) patients, inflammation, reduced activity, and medication have a negative impact on the musculoskeletal system. Several endocrine factors are involved in muscle growth and bone turnover. OBJECTIVE: We aimed to investigate factors regulating myogenesis and bone metabolism and to evaluate possible associations between these endocrine factors, muscle strength, and functional tests in DM patients. METHODS: We conducted a cross-sectional study in 20 dermatomyositis patients. Serum levels of myostatin (MSTN), follistatin (FSTN), dickkopf 1 (Dkk1), sclerostin (SOST), periostin (PSTN), the receptor activator nuclear factor kB ligand (RANKL):osteoprotegerin (OPG) ratio and fibroblast growth factor 23 (FGF23) were determined. Physical function was evaluated by hand-held strength measurement, chair rising test, timed up and go test and the 3-min walking test. RESULTS: Serum MSTN and FGF23 levels (2.5 [1.9; 3.2] vs. 1.9 [1.6; 2.3] and 2.17 [1.45; 3.26] vs. 1.28 [0.79; 1.96], respectively; p < 0.05) were significantly higher in DM patients than in controls. Dkk1 was significantly lower (11.4 [6.9; 20.0] vs. 31.8 [14.3; 50.6], p < 0.01). Muscle strength and physical function tests correlated with each other (e.g. hip flexion - timed up and go test: r = - 0.748, p < 0.01). CONCLUSION: In DM patients, biochemical musculo-skeletal markers are altered and physical function shows deficits. All these tests reflect independent of each other different deficits in long-term DM patients which is important for the assessment of DM patients as well as planning of therapeutic interventions in clinical routine.
BACKGROUND: In dermatomyostis (DM) patients, inflammation, reduced activity, and medication have a negative impact on the musculoskeletal system. Several endocrine factors are involved in muscle growth and bone turnover. OBJECTIVE: We aimed to investigate factors regulating myogenesis and bone metabolism and to evaluate possible associations between these endocrine factors, muscle strength, and functional tests in DMpatients. METHODS: We conducted a cross-sectional study in 20 dermatomyositispatients. Serum levels of myostatin (MSTN), follistatin (FSTN), dickkopf 1 (Dkk1), sclerostin (SOST), periostin (PSTN), the receptor activator nuclear factor kB ligand (RANKL):osteoprotegerin (OPG) ratio and fibroblast growth factor 23 (FGF23) were determined. Physical function was evaluated by hand-held strength measurement, chair rising test, timed up and go test and the 3-min walking test. RESULTS: Serum MSTN and FGF23 levels (2.5 [1.9; 3.2] vs. 1.9 [1.6; 2.3] and 2.17 [1.45; 3.26] vs. 1.28 [0.79; 1.96], respectively; p < 0.05) were significantly higher in DMpatients than in controls. Dkk1 was significantly lower (11.4 [6.9; 20.0] vs. 31.8 [14.3; 50.6], p < 0.01). Muscle strength and physical function tests correlated with each other (e.g. hip flexion - timed up and go test: r = - 0.748, p < 0.01). CONCLUSION: In DMpatients, biochemical musculo-skeletal markers are altered and physical function shows deficits. All these tests reflect independent of each other different deficits in long-term DMpatients which is important for the assessment of DMpatients as well as planning of therapeutic interventions in clinical routine.
Entities:
Keywords:
Dermatomyositis; FGF23; Muscle strength; Myostatin; Physical function
Authors: G F Wiesinger; M Quittan; M Nuhr; B Volc-Platzer; G Ebenbichler; M Zehetgruber; W Graninger Journal: Arch Phys Med Rehabil Date: 2000-01 Impact factor: 3.966
Authors: Malin Regardt; Elisabet Welin Henriksson; Helene Alexanderson; Ingrid E Lundberg Journal: Rheumatology (Oxford) Date: 2010-11-21 Impact factor: 7.580
Authors: I M Bronner; M F G van der Meulen; M de Visser; S Kalmijn; W J van Venrooij; A E Voskuyl; H J Dinant; W H J P Linssen; J H J Wokke; J E Hoogendijk Journal: Ann Rheum Dis Date: 2006-04-10 Impact factor: 19.103
Authors: Valentin David; Aline Martin; Tamara Isakova; Christina Spaulding; Lixin Qi; Veronica Ramirez; Kimberly B Zumbrennen-Bullough; Chia Chi Sun; Herbert Y Lin; Jodie L Babitt; Myles Wolf Journal: Kidney Int Date: 2016-01-04 Impact factor: 10.612